0.5671
前日終値:
$0.59
開ける:
$0.59
24時間の取引高:
297.77K
Relative Volume:
0.59
時価総額:
$70.80M
収益:
-
当期純損益:
$-112.46M
株価収益率:
-0.3458
EPS:
-1.64
ネットキャッシュフロー:
$-99.89M
1週間 パフォーマンス:
-24.68%
1か月 パフォーマンス:
-35.56%
6か月 パフォーマンス:
-15.52%
1年 パフォーマンス:
-72.74%
Vor Biopharma Inc Stock (VOR) Company Profile
VOR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
VOR
Vor Biopharma Inc
|
0.5671 | 70.80M | 0 | -112.46M | -99.89M | -1.64 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2022-07-26 | 開始されました | Wedbush | Outperform |
2022-04-27 | 開始されました | Goldman | Neutral |
2021-12-17 | 開始されました | H.C. Wainwright | Buy |
2021-12-03 | 開始されました | Robert W. Baird | Outperform |
2021-12-02 | 開始されました | Oppenheimer | Outperform |
2021-10-19 | 開始されました | JMP Securities | Mkt Outperform |
2021-03-25 | 開始されました | B. Riley Securities | Buy |
2021-03-03 | 開始されました | Barclays | Overweight |
2021-03-03 | 開始されました | Evercore ISI | Outperform |
2021-03-02 | 開始されました | Goldman | Sell |
2021-03-02 | 開始されました | Stifel | Buy |
すべてを表示
Vor Biopharma Inc (VOR) 最新ニュース
Vor Biopharma CMO resigns to pursue new opportunity - Investing.com Australia
Vor Biopharma’s Chief Medical Officer Resigns - TipRanks
Vor Bio Advances in Clinical Trials and Secures Funding - TipRanks
Vor Biopharma stock plunges to 52-week low of $0.63 - Investing.com
Vor Biopharma stock plunges to 52-week low of $0.63 By Investing.com - Investing.com South Africa
Virtu Financial LLC Makes New $60,000 Investment in Vor Biopharma Inc. (NYSE:VOR) - Defense World
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely - Yahoo Finance
Vor Biopharma Inc. (NYSE:VOR) Receives Average Rating of “Buy” from Analysts - Defense World
Oppenheimer Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR) - MarketBeat
Vor Biopharma’s SWOT analysis: stock outlook amid AML treatment progress By Investing.com - Investing.com Canada
Vor Biopharma’s SWOT analysis: stock outlook amid AML treatment progress - Investing.com India
Vor Biopharma stock holds $6 target, Market Outperform rating By Investing.com - Investing.com South Africa
Vor Biopharma stock holds $6 target, Market Outperform rating - Investing.com India
Citizens JMP Reiterates Market Outperform Rating on Vor Biopharma, Inc. (VOR) - StreetInsider
Vor Biopharma (NYSE:VOR) Price Target Cut to $5.00 by Analysts at Stifel Nicolaus - The AM Reporter
Stifel Nicolaus Has Lowered Expectations for Vor Biopharma (NYSE:VOR) Stock Price - Defense World
Oppenheimer Reiterates “Outperform” Rating for Vor Biopharma (NYSE:VOR) - Defense World
Wedbush Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR) - Defense World
Stifel cuts Vor Biopharma stock target to $5, maintains Buy rating - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Skye Bioscience (SKYE) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Stifel cuts Vor Biopharma stock target to $5, maintains Buy rating By Investing.com - Investing.com South Africa
Vor Biopharma, Inc. (VOR) PT Lowered to $5 at Stifel - StreetInsider.com
Vor Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update - MarketScreener
Vor Biopharma (VOR) Files $350M Mixed Shelf - StreetInsider.com
Vor Biopharma Inc. SEC 10-K Report - TradingView
Vor Biopharma Inc. (VOR) reports earnings - Quartz
Vor Biopharma revises stock option exercise prices - MSN
Vor Biopharma Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
BenitecAnother Biopharma Rocket - Barchart
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts - Defense World
Vor Biopharma: Short On Cash, Too Much Uncertainty For Now (VOR) - Seeking Alpha
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq - ACCESS Newswire
Vor biopharma chief medical officer sells $3,162 in stock By Investing.com - Investing.com Canada
Vor biopharma chief medical officer sells $3,162 in stock - Investing.com India
Pre-market Movers: TNXP, INBS, SMMT, NDRA... - RTTNews
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials - Yahoo Finance
Vor biopharma’s chief medical officer sells $3,498 in stock By Investing.com - Investing.com Nigeria
Vor biopharma's chief medical officer sells $3,498 in stock - MSN
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross - MSN
Brokerages Set Vor Biopharma Inc. (NYSE:VOR) PT at $11.36 - MarketBeat
Following A 1.65% Weekly Incline, Is It Still A Buy For Nerdy Inc (NYSE: NRDY)? - Marketing Sentinel
Vor Biopharma Inc (NASDAQ: VOR) Stock Falling -15.06% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Should Energy Vault Holdings Inc (NYSE: NRGV) Rally After -60.12% Drop From High? - Marketing Sentinel
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL): How Can A Stock Be Up 7.83% Year To Date, But Still Loser - Marketing Sentinel
Vor Biopharma revises stock option exercise prices By Investing.com - Investing.com Canada
VOR Shares Experience Surge in Value - Knox Daily
Vor Biopharma Approves Stock Option Repricing Strategy - TipRanks
Vor Biopharma Inc (VOR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):